Would a healthy person really take a cancer drug if it were free? This drug-by-drug analysis examines the degree to which eliminating OOP costs would raise premiums due to over-utilization (not just increased appropriate utilization). Many branded drugs are so unpleasant that it’s hard to imagine why someone would need an OOP cost to deter inappropriate utilization.
Feel free to reach out with questions, concerns, or comments.
Contact us